TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: Optimization of dosing regimens and schedules

Qian Liu, Jessica D. Sun, Jingli Wang, Dharmendra Ahluwalia, Amanda F. Baker, Lee D. Cranmer, Damien Ferraro, Yan Wang, Jian Xin Duan, W. Steve Ammons, John G. Curd, Mark D. Matteucci, Charles P. Hart

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Fingerprint

Dive into the research topics of 'TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: Optimization of dosing regimens and schedules'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds